BR112018001762A2 - anticorpos apenas de cadeia pesada para ang-2 - Google Patents

anticorpos apenas de cadeia pesada para ang-2

Info

Publication number
BR112018001762A2
BR112018001762A2 BR112018001762A BR112018001762A BR112018001762A2 BR 112018001762 A2 BR112018001762 A2 BR 112018001762A2 BR 112018001762 A BR112018001762 A BR 112018001762A BR 112018001762 A BR112018001762 A BR 112018001762A BR 112018001762 A2 BR112018001762 A2 BR 112018001762A2
Authority
BR
Brazil
Prior art keywords
antibodies
ang
heavy chain
antigen binding
pdgf
Prior art date
Application number
BR112018001762A
Other languages
English (en)
Portuguese (pt)
Inventor
W Gil Daniel
Liang Yanbin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112018001762A2 publication Critical patent/BR112018001762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018001762A 2015-07-29 2016-07-29 anticorpos apenas de cadeia pesada para ang-2 BR112018001762A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198518P 2015-07-29 2015-07-29
US201562205185P 2015-08-14 2015-08-14
PCT/US2016/044838 WO2017020001A2 (en) 2015-07-29 2016-07-29 Heavy chain only antibodies to ang-2

Publications (1)

Publication Number Publication Date
BR112018001762A2 true BR112018001762A2 (pt) 2018-09-18

Family

ID=56610025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001762A BR112018001762A2 (pt) 2015-07-29 2016-07-29 anticorpos apenas de cadeia pesada para ang-2

Country Status (13)

Country Link
US (3) US10266589B2 (enExample)
EP (2) EP3792279A3 (enExample)
JP (1) JP6916776B2 (enExample)
CN (1) CN107849126B (enExample)
AU (2) AU2016298398A1 (enExample)
BR (1) BR112018001762A2 (enExample)
CA (1) CA2992660A1 (enExample)
DK (1) DK3328886T3 (enExample)
ES (1) ES2828694T3 (enExample)
HU (1) HUE051165T2 (enExample)
PL (1) PL3328886T3 (enExample)
RU (1) RU2749674C2 (enExample)
WO (1) WO2017020001A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
HUE051165T2 (hu) * 2015-07-29 2021-03-01 Allergan Inc ANG-2 elleni, csak nehézláncot tartalmazó antitestek
WO2017030909A1 (en) * 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
WO2022098925A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CA2495621C (en) 2002-09-18 2008-02-12 Allergan, Inc. Methods and apparatus for delivery of ocular implants
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
CA2580336C (en) 2004-07-22 2016-07-19 Roger Kingdon Craig Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof
EP2457578B1 (en) * 2004-09-28 2015-08-19 Aprogen, Inc. Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction
KR101017301B1 (ko) * 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2746395C (en) * 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EA031182B1 (ru) * 2012-03-30 2018-11-30 Бёрингер Ингельхайм Интернациональ Гмбх Ang2-связывающие молекулы
CN104395339A (zh) * 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
MX361337B (es) 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
BR112015010722A2 (pt) * 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9902767B2 (en) * 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) * 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
CA2963723A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-pdgf-b antibodies and methods of use
HUE051165T2 (hu) * 2015-07-29 2021-03-01 Allergan Inc ANG-2 elleni, csak nehézláncot tartalmazó antitestek
WO2017030909A1 (en) * 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf

Also Published As

Publication number Publication date
DK3328886T3 (da) 2020-11-02
AU2016298398A1 (en) 2018-02-08
EP3792279A3 (en) 2021-07-07
US20210324064A1 (en) 2021-10-21
US20190248882A1 (en) 2019-08-15
RU2018103960A (ru) 2019-08-28
ES2828694T3 (es) 2021-05-27
CN107849126B (zh) 2022-04-08
PL3328886T3 (pl) 2021-02-08
CA2992660A1 (en) 2017-02-02
WO2017020001A3 (en) 2017-03-16
US20170107279A1 (en) 2017-04-20
RU2018103960A3 (enExample) 2020-01-16
RU2749674C2 (ru) 2021-06-16
HUE051165T2 (hu) 2021-03-01
HK1253947A1 (en) 2019-07-05
WO2017020001A2 (en) 2017-02-02
US10266589B2 (en) 2019-04-23
AU2022259761A1 (en) 2022-12-01
JP2018527327A (ja) 2018-09-20
EP3328886B1 (en) 2020-09-16
EP3792279A2 (en) 2021-03-17
EP3328886A2 (en) 2018-06-06
CN107849126A (zh) 2018-03-27
US11046756B2 (en) 2021-06-29
JP6916776B2 (ja) 2021-08-11

Similar Documents

Publication Publication Date Title
BR112018001762A2 (pt) anticorpos apenas de cadeia pesada para ang-2
IL323322A (en) Bispecific antibody constructs that bind to target cell surface antigen and cd3 epsilon chain, compositions containing them and uses thereof
IL264334A (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
HUE066651T2 (hu) CD3-t kötõ antitestek
IL263083A (en) single chain variable segment cd3 binding proteins
HUE055112T2 (hu) Bispecifikus antitest konstrukciói, amelyek DLL3-hoz és CD3-hoz kötõdnek
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
WO2013136186A3 (en) Readily isolated bispecific antibodies with native immunoglobulin format
EP3471773A4 (en) ANTIBODIES BINDING CD3
MX390190B (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
DK3328893T3 (da) Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3
PE20180773A1 (es) Anticuerpos biespecificos para pd1 y tim3
SG11201803675RA (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX357011B (es) Anticuerpos biespecificos heterodimericos.
EP3294766C0 (en) HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CR20150575A (es) Anticuerpos humanos pac1
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
DK4258865T3 (da) Tungkæde-antistoffer
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2733 DE 23-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.